Literature DB >> 22409554

Comparison of triple quadrupole and high-resolution TOF-MS for quantification of peptides.

Lieve Dillen1, Willy Cools, Liesbeth Vereyken, Willy Lorreyne, Tinne Huybrechts, Ronald de Vries, Hesham Ghobarah, Filip Cuyckens.   

Abstract

BACKGROUND: With an increased interest in peptides and proteins as potential new drug candidates, new approaches for sensitive and selective quantitative analysis are required. LC-MS/MS analysis provides a good alternative to immunoassays with reduced method development times and increased specificity.
RESULTS: We have evaluated two state-of-the-art triple quadrupole and high-resolution TOF mass spectrometers with respect to their performance for quantification of six peptides (glufibrinopeptide B, somatostatin, enfuvirtide, TRI1144, C34 and exenatide). The peptides were spiked into protein-precipitated plasma supernatant. Triple quadrupole quantification was performed in SRM mode, and in high-resolution, MS narrow-width extracted chromatograms were generated for quantification. Specificity, accuracy, reproducibility and robustness were found to be comparable between the two instruments. The triple quadrupole instrument is still the most sensitive instrument for quantification of peptides with a median factor of about four-times higher sensitivity (based on LLOQ evaluation).
CONCLUSION: Based on sensitivity, the newest generation triple quadrupole MS systems are still the preferred technology for quantification of peptides. Since the sensitivity difference between triple quadrupole instruments and the new-generation high-resolution TOF-MS instruments is minor, the latter offer a useful alternative whenever additional selectivity is preferred or the use of a generic approach not requiring method optimization is advantageous.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22409554     DOI: 10.4155/bio.12.3

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  7 in total

Review 1.  DNA adducts: Formation, biological effects, and new biospecimens for mass spectrometric measurements in humans.

Authors:  Byeong Hwa Yun; Jingshu Guo; Medjda Bellamri; Robert J Turesky
Journal:  Mass Spectrom Rev       Date:  2018-06-11       Impact factor: 10.946

2.  Validation of a dual LC-HRMS platform for clinical metabolic diagnosis in serum, bridging quantitative analysis and untargeted metabolomics.

Authors:  Ilya Gertsman; Jon A Gangoiti; Bruce A Barshop
Journal:  Metabolomics       Date:  2014-04-04       Impact factor: 4.290

3.  Lipid-induced epigenomic changes in human macrophages identify a coronary artery disease-associated variant that regulates PPAP2B Expression through Altered C/EBP-beta binding.

Authors:  Michael E Reschen; Kyle J Gaulton; Da Lin; Elizabeth J Soilleux; Andrew J Morris; Susan S Smyth; Christopher A O'Callaghan
Journal:  PLoS Genet       Date:  2015-04-02       Impact factor: 5.917

4.  Personalized Proteomics: The Future of Precision Medicine.

Authors:  Trevor T Duarte; Charles T Spencer
Journal:  Proteomes       Date:  2016-10-01

5.  Ultra-high-performance liquid chromatography for the determination of exenatide in monkey plasma by tandem quadrupole mass spectrometry.

Authors:  Jin-Feng Zhang; Chun-Jie Sha; Yu Sun; Yun-Yun Gai; Ji-Ye Sun; Jiang-Bin Han; Xin Shao; Chun-Na Sha; You-Xin Li; Wan-Hui Liu
Journal:  J Pharm Anal       Date:  2012-12-28

6.  A robust, single-injection method for targeted, broad-spectrum plasma metabolomics.

Authors:  Kefeng Li; Jane C Naviaux; A Taylor Bright; Lin Wang; Robert K Naviaux
Journal:  Metabolomics       Date:  2017-09-04       Impact factor: 4.290

7.  Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant/advanced fibrosis in patients with nonalcoholic fatty liver disease.

Authors:  Wei Hou; Michael G Janech; Philip M Sobolesky; Alison M Bland; Salma Samsuddin; William Alazawi; Wing-Kin Syn
Journal:  Biosci Rep       Date:  2020-01-31       Impact factor: 3.840

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.